Supplementary Text and Figures

b

100 90

80

Barticle size (nm)60
50
40
30

20

d

1.E+10

1.E+09 1.E+07 1.E+06 1.E+05 1.E+04 1.E+03 1.E+02


1.E+01


Total Fluorescence Intensity

a

	1x DOTAP/ Cholesterol	2x DOTAP/ Cholesterol	3x DOTAP/ Cholesterol
1x Protamine	LPR-1	LPR-4	LPR-7
2x Protamine	LPR-2	LPR-5	LPR-8
3x Protamine	LPR-3	LPR-6	LPR-9

C





f


	BUN	AST	ALT
PBS treated	16±2.8	140.5±10.6	55.5±9.1
LPR treated	23±2.3	189±20	51.7±0.9
Normal Range	8~33	54~298	17~77

LPR-1 LPR-2 LPR-3 LPR-4 LPR-5 LPR-6 LPR-7 LPR-8 LPR-9


Size ——Zeta Potential

40

g



h



Supplementary Materials: (a) Matrix showing the designation of LPR formulation in each combination of various amounts of protamine and DOTAP/cholesterol. Different amounts of protamine and DOTAP/chol liposome were used to complex with mRNA to form LPR nanoparticles. The number indicated the charge ratio (N/P ratio) between the cationic liposomes used (or protamine) and anionic nucleic acids. (b) Particle size and zeta potential characterization with various formulations. The data are reported as mean±SD. (c) Gel retardation assay of mRNA and LPR complexes. Naked mRNA or LPR particles were incubated with 10% serum before loaded on a 0.7% agarose gel. 1) Serum sample is loaded for background control; 2) Untreated naked mRNA is loaded as a positive control; 3) Naked mRNA was incubated with serum before loaded on the gel; 4) LPR was incubated with serum before loaded; 5) LPR was firstly incubated with serum and then decomplexed with SDS before loaded on the gel; 6) Untreated LPR loaded as a control. (d) Quantification of LPR-mediated **H460 transfection efficiency.** Percent of transfected cells and total green fluorescent protein expression for the H460 cells transfected with nanoparticles at various formulations. The data were reported as mean±SD. (e) H&E staining of major organs from CD-1 mice that received multiple doses of LRP. (f) Hepatocytotoxicity and renal toxicity determined by AST/ALT and BUN respectively after repetitive systemic administration of LPR to CD-1 mice. (g) Monitoring of animal weight during the treatment. All the values were normalized based on the initial weight of the animals from corresponding group. The data were reported as mean±SD. (h) Western Blot analysis of homogenates of tumors from animals that received treatment of LPR or LPD nanoparticles. HSV-tk was blotted for the confirmation of expression and the expression level was compared as β -actin was blotted as a loading control.